Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 452,800 shares, a growth of 112.2% from the February 13th total of 213,400 shares. Currently, 2.7% of the company’s stock are short sold. Based on an average trading volume of 358,400 shares, the days-to-cover ratio is presently 1.3 days.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.
Get Our Latest Research Report on ACXP
Acurx Pharmaceuticals Price Performance
Insiders Place Their Bets
In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the stock in a transaction dated Monday, January 6th. The shares were purchased at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the acquisition, the chief executive officer now directly owns 1,097,458 shares in the company, valued at $1,108,432.58. This trade represents a 4.70 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 29.60% of the company’s stock.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 329,076 shares of the company’s stock after acquiring an additional 34,001 shares during the quarter. Prospect Financial Services LLC owned approximately 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent quarter. 11.53% of the stock is owned by institutional investors and hedge funds.
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Featured Stories
- Five stocks we like better than Acurx Pharmaceuticals
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Why Invest in High-Yield Dividend Stocks?
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- How to Read Stock Charts for Beginners
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.